Stopping tau proteins from sticking together to form toxic seeds.
Promoting the removal of pathological tau via microglia or through intracellular degradation pathways like the proteasome. Key Therapeutic Strategies antitauon
Current research focuses on both to combat these tauon species: Example Agents / Trials Passive Immunotherapy Stopping tau proteins from sticking together to form
The concept of "tauons" arises from the observation that misfolded tau protein isoforms can propagate through the brain in a characteristic pattern, similar to prions, driving the progression of conditions like Alzheimer's disease. Antitauon therapies aim to intervene in this process through several key mechanisms: Antitauon therapies aim to intervene in this process
Small Phase I studies have shown ASOs are safe and can reduce aggregated tau. Current Challenges and Clinical Status
Using antibodies to bind to extracellular tau species, preventing them from being taken up by healthy neighboring neurons.
Using antisense oligonucleotides (ASOs) or "intrabodies" to reduce tau levels within the cell.